Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Temperature Management Devices Are Hot

This article was originally published in Start Up

Executive Summary

Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. This has given rise to a group of medical device companies formed in the mid-to-late 1990s dedicated to developing temperature management systems. The big question has ben whether clinical data would validate the bets these companies made in this space. Early clinical data released recently has been positive, and large companies are interested in this area, sparking the first major temperature management deal.

You may also be interested in...

Philips buys Innercool: The Ice Age Cometh

As part of a bid to connect the dots between its own product offerings, Philips Healthcare acquired InnerCool Therapies, maker of surface and endovascular cooling devices for the management of cardiac patients. InnerCool fits into the company's broader "care cycle" strategy, the point of which is to provide a continuum of care to patients in the diseases Philips serves. Specifically, Philips' strategy is to connect diverse care settings to its product markets, in this case, cardiac resuscitation. The combination marks a change in how sudden cardiac arrest is regarded, from an isolated episode focused on a stopped heart to a larger strategy of patient management.

Where are They Now? Yesterday's Stroke Companies

In May 2000, START-UP profiled five medical device companies targeting stroke, in an article entitled "Making Progress in Stroke." We recently revisited Radiant Medical, Medivance, MicroVention, and two others to find out what went according to plan and what didn't In 2007, we have to say that there has in fact not been much progress, at least in acute ischemic stroke. Two companies dropped out, two remain active with promising programs--in clinical areas other than stroke, and one, which avoided ischemic stroke in the first place, enjoyed a nice exit.

Medivance: Climate Control for the Body

Physicians have long theorized that being able to precisely warm and cool patients, depending on their conditions and settings, would be beneficial in both cardiovascular and neurological procedures, and recent clinical evidence has shown temperature management to be even more important than initially thought.Medivance is looking to develop a non-invasive external temperature management system that is both simple to operate and suitable for a variety of settings for both precise warming and cooling. The company believes an external device avoids the risk of an invasive procedure and can be used easily by neurologists, who generally aren't comfortable inserting catheters.In striving to solve a difficult technology problem (external, non-invasive temperature management) with an easy-to-use device, Medivance is looking to avoid a problem that plagues many device companies--falling in love with complex, hard-to-operate technology. While a very sophisticated device may work effectively, a steep learning curve inhibits broad adoption because physicians are notoriously reluctant to adopt new technology unless it closely resembles current techniques. Medivance's system enables an anesthesiologist to regulate patient temperature without intruding on the surgical field and without heating up the OR, a win-win for surgeons.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts